Latest Becton Dickinson and Company (BDX) Headlines
Why Endologix (ELGX) Could Be Positioned for a Slump - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 7:43AM CDT
It may be a good decision to sell Endologix as its price dropped significantly in the past four weeks, the stock witnessed a negative trend in earnings estimate revisions and a poor Zacks Rank confirms weakness.
Patterson Companies Down to Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 5:15PM CDT
Patterson continues to face a challenging macro environment due to uncertainties surrounding the U.S. healthcare system as well as the ongoing austerity measures that have dampened demand for the past few years.
Quest Diagnostics to Buy Summit Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:00PM CDT
Post acquisition, Summit Health's services will complement the health and wellness business of Quest Diagnostics.
Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Wed Mar 12, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mdgmns/rapid_medical) has announced the addition of the "Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rapid medical diagnostic kits market is experiencing impressive growth globally because of the continuous increase in demand for preventive management of infectious diseases. Since its introduction, rapid medical diagnostic kits are becoming a vital part of the medical diagnostics industry and the scope of this market has been perpetually increasing in terms of detectable diseases and adoption by end users. This report studies the global market for rapid diagnostic kits through three major perspectives namely, application areas, technologies and geography. The application segment of this market has been further segmented into three sub-divisions namely clinical testing, home-use and veterinary diagnostics. In addition, the technology segment of rapid medical diagnostic kits market has been categorized into lateral flow, flow-through, agglutination assays and solid phase. Each of the above segments are analyzed on the basis of their market size (in terms of USD million) for the period 2011 to 2019. This also includes the forecast of the market segments in terms of CAGR (%) for the period 2013 - 2019, considering 2012 as the base year. Geographically, the rapid medical diagnostic kits market is categorized into four regions namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market revenues (for the period 2011 - 2019) and forecast (for the period 2013 - 2019) for each of these regions have been included in this report. The market overview section of the report demonstrates the qualitative analysis of the market dynamics of the global rapid medical diagnostic kits market and thus includes information about the drivers, restraints, opportunities, Porter's five forces model and market attractiveness analysis of this industry. Key Topics Covered: Introduction Executive Summary Rapid Medical Diagnostic Kits Market Overview Global Rapid Medical Diagnostic Kits Market, by Applications, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Technology, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Geography, 2011 - 2019, (USD Million) Recommendations Competitive Landscape Companies Mentioned - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - Danaher Corporation (Beckman Coulter) - MegaCor Diagnostik GmbH - F. Hoffmann-La Roche Ltd. - Trinity Biotech plc - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/md...id_medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Quest Diagnostics Ups View on Solstas Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 4:20PM CDT
With the declaration of the closure of its earlier announced acquisition of Solstas Lab Partners Group and its subsidiaries, Quest Diagnostics also raised its 2014 financial outlook.
DENTSPLY International Raised to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 2:30PM CDT
Positive earnings guidance and anticipated improvement in the global market conditions in 2014, combined with improving leveraged position and margins, represent a potential upside for DENTSPLY going forward.
Intravenous Access Devices Market Trends & Forecasts, 2019 - Needles, Catheters & Infusion Pumps
M2 - Tue Mar 11, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/85klhj/intravenous) has announced the addition of the "Intravenous Access Devices Market Trends & Forecast, 2019 - Needles, Catheters & Infusion Pumps" report to their offering. This report studies the market for intravenous (IV) access devices utilized by physicians to deliver medication to the patients' bloodstream through the intravenous route and also to withdraw blood for testing purpose. The global intravenous access devices market is segmented into four categories in this report, namely, IV needles, IV catheters and IV infusion pumps. These product segments have been further classified based on the type of products. The intravenous catheters segment includes midline peripheral catheters and central catheters. Central catheters are further classified as peripherally inserted central catheters (PICC) and centrally inserted catheters. The intravenous infusion pumps segment includes insulin infusion pumps, parenteral feeding infusion pumps, patient controlled analgesia (PCA) infusion pumps and syringe infusion pumps. The report also includes a market overview section that discusses the drivers, restraints and opportunities in the market. In addition, it also provides Porter's five force analysis and market attractiveness analysis for the global intravenous access devices market. Market share in terms of percentage (for 2012) for major industry players has also been provided in the report along with a list of recommendations for new as well as existing players of the market. The report concludes with company profiles of the companies operating in this market, with details such as company overview, financial overview, product portfolio, business strategies and recent developments of each company. Some of the prominent players profiled in the report are Hospira, Inc., Becton, Dickinson & Company, CareFusion Corporation, Baxter International, Medtronic, Inc. and Covidien Plc. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Intravenous Access Devices Market, by Product Type Chapter 5 Global Intravenous Access Devices Market, by Geography Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles For more information visit http://www.researchandmarkets.com/research/85...ntravenous
Balanced View Continues for Henry Schein - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 1:50PM CDT
On Mar 07, 2014, we issued an updated research report on Henry Schein Inc.
Cooper Companies Beats on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 1:32PM CST
For fiscal 2014, COO now expects total revenues between $ 1,685 and $1,725 million compared with the prior guidance of $1,675 and $1,735 million.
Bio-Reference Laboratories (BRLI) Falls: Stock Goes Down 5.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:42AM CST
Bio-Reference Laboratories saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell over 5% on the day.
Safeguard Scientifics Announces Fourth Quarter and Full-Year 2013 Financial Results
Business Wire - Thu Mar 06, 5:00AM CST
--Company Increases Share Repurchase Program;
3 Stocks Going Ex-Dividend Tomorrow: FAF, CNI, BDX
at The Street - Wed Mar 05, 9:00AM CST
FAF CNI BDX are going ex-dividend tomorrow, Thursday, March 6, 2014, 5:00 AM ET
Weakness Seen in STAAR Surgical (STAA) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 7:46AM CST
STAAR Surgical has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month.
Henry Schein, P&G Sign Distribution Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 3:00PM CST
Recently, Henry Schein inked a distribution deal with The Procter & Gamble Company.
Progress Watch Corp. to Enter Social/Content Marketing Arena
Marketwire - Tue Feb 25, 9:13AM CST
Progress Watch Corporation (PINKSHEETS: PROW) announced that it will enter the social/ content marketing arena. With more than one billion smart phone users and 1.7 billion expected by 2017, this move from its traditional core business line mechanical movement manufacturing and watch supply businesses) is expected to develop new revenue streams for the company, especially in the area of social/content marketing. Companies will have the ability to target specific markets to stream branded messages.
BD to Present at Investor Healthcare Conferences
PR Newswire - Tue Feb 25, 7:00AM CST
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following investor healthcare conferences in March 2014:
Healthcare Providers Can Diagnose Group A Strep in Minutes with New Test
PR Newswire - Tue Feb 25, 7:00AM CST
BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) Waiver from the U.S. Food and Drug Administration (FDA) for the BD Veritor(TM) System for Rapid Detection of Group A Strep. This is the first commercially available rapid Group A Strep test system that incorporates a digital result to receive CLIA Waiver. The new assay is cleared for use in hospitals, outpatient clinics and other patient-care settings.
A Whole New Opportunity For Hologic Inc?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Feb 24, 5:30PM CST
Women's health specialist Hologic has had a rough go of it. At a time when most companies in the medical equipment or diagnostics markets can look back on a great two-year run in their share prices, Hologic's shares have chopped around and gone...
Molecular Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Mon Feb 24, 5:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/x9dvt9/molecular) has announced the addition of the "Molecular Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Molecular diagnostics primarily refers to a class of diagnostic test that analyzes nucleic acids or proteins at a molecular level. This class of diagnostics is identified as rapidly evolving and fastest growing segment of in-vitro diagnostics industry. Moreover, it is also considered as the most attractive and well established market for clinical applications. Traditionally, usage of molecular diagnostics was limited due to requirement of highly skilled professionals and high cost of tests. But reduction in cost per sample analysis and labor cost, improvements in automation and introduction of advanced technologies has expanded the usage of molecular diagnostics in wide range of applications. The market for molecular diagnostics has expanded since 1990's with the introduction of PCR test for HIV and Chlamydia Trachomatis/Neisseria Gonorrhoeae (CT/NG). It is estimated that in the U.S. over 600 laboratories and 200 independent laboratories perform molecular diagnostics test to simplify and accelerate the testing process. Nowadays, molecular diagnostics tests are widely being adopted for testing infectious diseases (HIV, HCV, HPV HAI and others), genetic diseases, cancer testing and HLA testing. Similarly, molecular diagnostic kits are being used for blood donor screening and pharmacogenetics testing. Growth of this market in various segments is fuelled by the rise in incidence of chronic infections, growing geriatric population, increasing investments in R&D and increasing demand for personalized medicines. Currently, molecular diagnostics revenue is dominated by infectious diseases, capturing more 50% of the market share. Furthermore, growth of this segment will be triggered by rising incidences of hospital acquired infections (HAI) and thus HAI testing market is expected to witness a fastest growth rate in near future. This market is poised to grow at a CAGR of 15.1% from 2013-2019. HAI is being identified as a major cause of death and morbidity among hospitalized patients. It is estimated that each year approximately 14,000 Americans are diagnosed with C.difficile hospital acquired infection each year. Therefore, hospitals continue to adopt HAI testing as more virulent strains of these infections continue to surge. Similarly, rising cancer incidence is expected to drive the market for oncology testing and HPV testing during the analysis period. Next generation sequencing is growing rapidly and is estimated to emerge as the fastest growing segment. The technique is gaining importance owing to its rapid turnaround time, sensitivity and reduction in cost of sequencing. PCR market that accounted for a maximum share of the total molecular diagnostics market in 2012 is estimated to decline due to evolution of high throughput sequencing techniques. Key Topics Covered - Preface - Executive Summary - Market Overview - Molecular Diagnostics Market, by Technology - Global Molecular Diagnostics Market, by Applications - Global Molecular Diagnostics Market, by Geography - Global Molecular Diagnostics Market Share Analysis - Recommendations - Company Profiles Companies Mentioned - Abbott Laboratories - Becton Dickinson & Company - Bio-Rad - bioMerieux - Cepheid - Danaher Corporation (Beckman Coulter) - F. Hoffmann-La Roche - Hologic (Gen-Probe) - Myriad Genetics - Novartis International - Qiagen - Quest Diagnostics - Siemens - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/x9dvt9/molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Should You Follow Carl Icahn Into This Health Care Turnaround?
Bob Chandler, The Motley Fool - Motley Fool - Sun Feb 23, 3:43PM CST
Investor Carl Icahn has an eye for a good buy. With a remarkable ability to bring out unrecognized value in his share purchases, he has amassed a fortune. And now it appears he believes medical device maker Hologic may possess some hidden worth....
Why Endologix (ELGX) Could Be Positioned for a Slump - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 7:43AM CDT
It may be a good decision to sell Endologix as its price dropped significantly in the past four weeks, the stock witnessed a negative trend in earnings estimate revisions and a poor Zacks Rank confirms weakness.
Patterson Companies Down to Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 5:15PM CDT
Patterson continues to face a challenging macro environment due to uncertainties surrounding the U.S. healthcare system as well as the ongoing austerity measures that have dampened demand for the past few years.
Quest Diagnostics to Buy Summit Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:00PM CDT
Post acquisition, Summit Health's services will complement the health and wellness business of Quest Diagnostics.
Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Wed Mar 12, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mdgmns/rapid_medical) has announced the addition of the "Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rapid medical diagnostic kits market is experiencing impressive growth globally because of the continuous increase in demand for preventive management of infectious diseases. Since its introduction, rapid medical diagnostic kits are becoming a vital part of the medical diagnostics industry and the scope of this market has been perpetually increasing in terms of detectable diseases and adoption by end users. This report studies the global market for rapid diagnostic kits through three major perspectives namely, application areas, technologies and geography. The application segment of this market has been further segmented into three sub-divisions namely clinical testing, home-use and veterinary diagnostics. In addition, the technology segment of rapid medical diagnostic kits market has been categorized into lateral flow, flow-through, agglutination assays and solid phase. Each of the above segments are analyzed on the basis of their market size (in terms of USD million) for the period 2011 to 2019. This also includes the forecast of the market segments in terms of CAGR (%) for the period 2013 - 2019, considering 2012 as the base year. Geographically, the rapid medical diagnostic kits market is categorized into four regions namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market revenues (for the period 2011 - 2019) and forecast (for the period 2013 - 2019) for each of these regions have been included in this report. The market overview section of the report demonstrates the qualitative analysis of the market dynamics of the global rapid medical diagnostic kits market and thus includes information about the drivers, restraints, opportunities, Porter's five forces model and market attractiveness analysis of this industry. Key Topics Covered: Introduction Executive Summary Rapid Medical Diagnostic Kits Market Overview Global Rapid Medical Diagnostic Kits Market, by Applications, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Technology, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Geography, 2011 - 2019, (USD Million) Recommendations Competitive Landscape Companies Mentioned - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - Danaher Corporation (Beckman Coulter) - MegaCor Diagnostik GmbH - F. Hoffmann-La Roche Ltd. - Trinity Biotech plc - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/md...id_medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Quest Diagnostics Ups View on Solstas Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 4:20PM CDT
With the declaration of the closure of its earlier announced acquisition of Solstas Lab Partners Group and its subsidiaries, Quest Diagnostics also raised its 2014 financial outlook.
DENTSPLY International Raised to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 2:30PM CDT
Positive earnings guidance and anticipated improvement in the global market conditions in 2014, combined with improving leveraged position and margins, represent a potential upside for DENTSPLY going forward.
Intravenous Access Devices Market Trends & Forecasts, 2019 - Needles, Catheters & Infusion Pumps
M2 - Tue Mar 11, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/85klhj/intravenous) has announced the addition of the "Intravenous Access Devices Market Trends & Forecast, 2019 - Needles, Catheters & Infusion Pumps" report to their offering. This report studies the market for intravenous (IV) access devices utilized by physicians to deliver medication to the patients' bloodstream through the intravenous route and also to withdraw blood for testing purpose. The global intravenous access devices market is segmented into four categories in this report, namely, IV needles, IV catheters and IV infusion pumps. These product segments have been further classified based on the type of products. The intravenous catheters segment includes midline peripheral catheters and central catheters. Central catheters are further classified as peripherally inserted central catheters (PICC) and centrally inserted catheters. The intravenous infusion pumps segment includes insulin infusion pumps, parenteral feeding infusion pumps, patient controlled analgesia (PCA) infusion pumps and syringe infusion pumps. The report also includes a market overview section that discusses the drivers, restraints and opportunities in the market. In addition, it also provides Porter's five force analysis and market attractiveness analysis for the global intravenous access devices market. Market share in terms of percentage (for 2012) for major industry players has also been provided in the report along with a list of recommendations for new as well as existing players of the market. The report concludes with company profiles of the companies operating in this market, with details such as company overview, financial overview, product portfolio, business strategies and recent developments of each company. Some of the prominent players profiled in the report are Hospira, Inc., Becton, Dickinson & Company, CareFusion Corporation, Baxter International, Medtronic, Inc. and Covidien Plc. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Intravenous Access Devices Market, by Product Type Chapter 5 Global Intravenous Access Devices Market, by Geography Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles For more information visit http://www.researchandmarkets.com/research/85...ntravenous
Balanced View Continues for Henry Schein - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 1:50PM CDT
On Mar 07, 2014, we issued an updated research report on Henry Schein Inc.
Cooper Companies Beats on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 1:32PM CST
For fiscal 2014, COO now expects total revenues between $ 1,685 and $1,725 million compared with the prior guidance of $1,675 and $1,735 million.
Bio-Reference Laboratories (BRLI) Falls: Stock Goes Down 5.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:42AM CST
Bio-Reference Laboratories saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell over 5% on the day.
Safeguard Scientifics Announces Fourth Quarter and Full-Year 2013 Financial Results
Business Wire - Thu Mar 06, 5:00AM CST
--Company Increases Share Repurchase Program;
3 Stocks Going Ex-Dividend Tomorrow: FAF, CNI, BDX
at The Street - Wed Mar 05, 9:00AM CST
FAF CNI BDX are going ex-dividend tomorrow, Thursday, March 6, 2014, 5:00 AM ET
Weakness Seen in STAAR Surgical (STAA) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 7:46AM CST
STAAR Surgical has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month.
Henry Schein, P&G Sign Distribution Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 3:00PM CST
Recently, Henry Schein inked a distribution deal with The Procter & Gamble Company.
Progress Watch Corp. to Enter Social/Content Marketing Arena
Marketwire - Tue Feb 25, 9:13AM CST
Progress Watch Corporation (PINKSHEETS: PROW) announced that it will enter the social/ content marketing arena. With more than one billion smart phone users and 1.7 billion expected by 2017, this move from its traditional core business line mechanical movement manufacturing and watch supply businesses) is expected to develop new revenue streams for the company, especially in the area of social/content marketing. Companies will have the ability to target specific markets to stream branded messages.
BD to Present at Investor Healthcare Conferences
PR Newswire - Tue Feb 25, 7:00AM CST
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following investor healthcare conferences in March 2014:
Healthcare Providers Can Diagnose Group A Strep in Minutes with New Test
PR Newswire - Tue Feb 25, 7:00AM CST
BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) Waiver from the U.S. Food and Drug Administration (FDA) for the BD Veritor(TM) System for Rapid Detection of Group A Strep. This is the first commercially available rapid Group A Strep test system that incorporates a digital result to receive CLIA Waiver. The new assay is cleared for use in hospitals, outpatient clinics and other patient-care settings.
A Whole New Opportunity For Hologic Inc?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Feb 24, 5:30PM CST
Women's health specialist Hologic has had a rough go of it. At a time when most companies in the medical equipment or diagnostics markets can look back on a great two-year run in their share prices, Hologic's shares have chopped around and gone...
Molecular Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Mon Feb 24, 5:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/x9dvt9/molecular) has announced the addition of the "Molecular Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Molecular diagnostics primarily refers to a class of diagnostic test that analyzes nucleic acids or proteins at a molecular level. This class of diagnostics is identified as rapidly evolving and fastest growing segment of in-vitro diagnostics industry. Moreover, it is also considered as the most attractive and well established market for clinical applications. Traditionally, usage of molecular diagnostics was limited due to requirement of highly skilled professionals and high cost of tests. But reduction in cost per sample analysis and labor cost, improvements in automation and introduction of advanced technologies has expanded the usage of molecular diagnostics in wide range of applications. The market for molecular diagnostics has expanded since 1990's with the introduction of PCR test for HIV and Chlamydia Trachomatis/Neisseria Gonorrhoeae (CT/NG). It is estimated that in the U.S. over 600 laboratories and 200 independent laboratories perform molecular diagnostics test to simplify and accelerate the testing process. Nowadays, molecular diagnostics tests are widely being adopted for testing infectious diseases (HIV, HCV, HPV HAI and others), genetic diseases, cancer testing and HLA testing. Similarly, molecular diagnostic kits are being used for blood donor screening and pharmacogenetics testing. Growth of this market in various segments is fuelled by the rise in incidence of chronic infections, growing geriatric population, increasing investments in R&D and increasing demand for personalized medicines. Currently, molecular diagnostics revenue is dominated by infectious diseases, capturing more 50% of the market share. Furthermore, growth of this segment will be triggered by rising incidences of hospital acquired infections (HAI) and thus HAI testing market is expected to witness a fastest growth rate in near future. This market is poised to grow at a CAGR of 15.1% from 2013-2019. HAI is being identified as a major cause of death and morbidity among hospitalized patients. It is estimated that each year approximately 14,000 Americans are diagnosed with C.difficile hospital acquired infection each year. Therefore, hospitals continue to adopt HAI testing as more virulent strains of these infections continue to surge. Similarly, rising cancer incidence is expected to drive the market for oncology testing and HPV testing during the analysis period. Next generation sequencing is growing rapidly and is estimated to emerge as the fastest growing segment. The technique is gaining importance owing to its rapid turnaround time, sensitivity and reduction in cost of sequencing. PCR market that accounted for a maximum share of the total molecular diagnostics market in 2012 is estimated to decline due to evolution of high throughput sequencing techniques. Key Topics Covered - Preface - Executive Summary - Market Overview - Molecular Diagnostics Market, by Technology - Global Molecular Diagnostics Market, by Applications - Global Molecular Diagnostics Market, by Geography - Global Molecular Diagnostics Market Share Analysis - Recommendations - Company Profiles Companies Mentioned - Abbott Laboratories - Becton Dickinson & Company - Bio-Rad - bioMerieux - Cepheid - Danaher Corporation (Beckman Coulter) - F. Hoffmann-La Roche - Hologic (Gen-Probe) - Myriad Genetics - Novartis International - Qiagen - Quest Diagnostics - Siemens - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/x9dvt9/molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Should You Follow Carl Icahn Into This Health Care Turnaround?
Bob Chandler, The Motley Fool - Motley Fool - Sun Feb 23, 3:43PM CST
Investor Carl Icahn has an eye for a good buy. With a remarkable ability to bring out unrecognized value in his share purchases, he has amassed a fortune. And now it appears he believes medical device maker Hologic may possess some hidden worth....
